Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 364

1.

RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study.

Bachet JB, Bouché O, Taieb J, Dubreuil O, Garcia ML, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, Bonnetain F, Thirot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Taly V, Blons H, Vernerey D, Laurent-Puig P.

Ann Oncol. 2018 Feb 9. doi: 10.1093/annonc/mdy061. [Epub ahead of print]

PMID:
29438522
2.

Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study).

Zaanan A, Samalin E, Aparicio T, Bouche O, Laurent-Puig P, Manfredi S, Michel P, Monterymard C, Moreau M, Rougier P, Tougeron D, Taieb J, Louvet C.

Dig Liver Dis. 2018 Feb 3. pii: S1590-8658(18)30133-6. doi: 10.1016/j.dld.2018.01.119. [Epub ahead of print]

PMID:
29409778
3.

RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014.

Lièvre A, Merlin JL, Sabourin JC, Artru P, Tong S, Libert L, Audhuy F, Gicquel C, Moureau-Zabotto L, Ossendza RA, Laurent-Puig P, Ducreux M.

Dig Liver Dis. 2018 Jan 8. pii: S1590-8658(18)30127-0. doi: 10.1016/j.dld.2017.12.029. [Epub ahead of print]

PMID:
29396127
4.

Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.

Bradley CA, Salto-Tellez M, Laurent-Puig P, Bardelli A, Rolfo C, Tabernero J, Khawaja HA, Lawler M, Johnston PG, Van Schaeybroeck S; MErCuRIC consortium.

Nat Rev Clin Oncol. 2018 Jan 23;15(3):150. doi: 10.1038/nrclinonc.2018.13. [Epub ahead of print]

PMID:
29358775
5.

Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial.

Pugh S, Thiébaut R, Bridgewater J, Grisoni ML, Moutasim K, Rousseau F, Thomas GJ, Griffiths G, Liebaert F, Primrose J, Laurent-Puig P.

Oncotarget. 2017 Sep 27;8(55):93856-93866. doi: 10.18632/oncotarget.21291. eCollection 2017 Nov 7.

6.

Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.

Taieb J, Kourie HR, Emile JF, Le Malicot K, Balogoun R, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Mulot C, Bouché O, Aparicio T, Michel P, Thaler J, Bridgewater J, Van Cutsem E, Perkins G, Lepage C, Salazar R, Laurent-Puig P; Pan-European Trials in Alimentary Tract Cancer (PETACC)-8 Investigators.

JAMA Oncol. 2017 Nov 22. doi: 10.1001/jamaoncol.2017.3695. [Epub ahead of print]

PMID:
29167892
7.

Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective.

Postel M, Roosen A, Laurent-Puig P, Taly V, Wang-Renault SF.

Expert Rev Mol Diagn. 2018 Jan;18(1):7-17. doi: 10.1080/14737159.2018.1400384. Epub 2017 Nov 13.

PMID:
29115895
8.

Mutational Diversity of Lung Cancer and Associated Lymph Nodes. An Exploratory Prospective Study of 4 Resected cIIIA-N2.

Legras A, Roussel H, Mangiameli G, Arame A, Grand B, Pricopi C, Badia A, Gibault L, Badoual C, Fabre E, Laurent-Puig P, Blons H, Le Pimpec-Barthes F.

Pathol Oncol Res. 2017 Nov 6. doi: 10.1007/s12253-017-0352-x. [Epub ahead of print]

PMID:
29110262
9.

[Lynch syndrome and endometrial cancer].

Bats AS, Rossi L, Le Frere-Belda MA, Narjoz C, Cournou C, Gosset M, Ngo C, Delomenie M, Nos C, Blons H, Laurent-Puig P, Lecuru F.

Bull Cancer. 2017 Dec;104(12):1013-1021. doi: 10.1016/j.bulcan.2017.06.018. Epub 2017 Oct 21. Review. French.

PMID:
29061399
10.

An architecture for genomics analysis in a clinical setting using Galaxy and Docker.

Digan W, Countouris H, Barritault M, Baudoin D, Laurent-Puig P, Blons H, Burgun A, Rance B.

Gigascience. 2017 Nov 1;6(11):1-9. doi: 10.1093/gigascience/gix099.

11.

Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.

Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA.

JAMA Oncol. 2017 Oct 5. doi: 10.1001/jamaoncol.2017.2899. [Epub ahead of print]

PMID:
28983557
12.

The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.

Marisa L, Svrcek M, Collura A, Becht E, Cervera P, Wanherdrick K, Buhard O, Goloudina A, Jonchère V, Selves J, Milano G, Guenot D, Cohen R, Colas C, Laurent-Puig P, Olschwang S, Lefèvre JH, Parc Y, Boige V, Lepage C, André T, Fléjou JF, Dérangère V, Ghiringhelli F, de Reynies A, Duval A.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx136.

PMID:
28922790
13.

A comprehensive characterization of the impact of mycophenolic acid on the metabolism of Jurkat T cells.

Fernández-Ramos AA, Marchetti-Laurent C, Poindessous V, Antonio S, Petitgas C, Ceballos-Picot I, Laurent-Puig P, Bortoli S, Loriot MA, Pallet N.

Sci Rep. 2017 Sep 5;7(1):10550. doi: 10.1038/s41598-017-10338-6.

14.

Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer.

Legras A, Pécuchet N, Imbeaud S, Pallier K, Didelot A, Roussel H, Gibault L, Fabre E, Le Pimpec-Barthes F, Laurent-Puig P, Blons H.

Cancers (Basel). 2017 Aug 3;9(8). pii: E101. doi: 10.3390/cancers9080101. Review.

15.

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

Emile JF, Julié C, Le Malicot K, Lepage C, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Dimet S, Boulagnon-Rombi C, Allard MA, Penault-Llorca F, Bennouna J, Laurent-Puig P, Taieb J; PETACC8 Study Investigators; Austrian Breast and Colorectal cancer Study Group (ABCSG); Belgian Group of Digestive Oncology (BGDO); Lone Nørgård Petersen; Fédération Francophone de Cancérologie Digestive (FFCD); Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER); Fédération Nationale des Centres de Lutte Contre le Cancer Association Européenne de Recherche en Oncologie (AERO); Arbeitsgemeinschaft Internistische Onkologie (AIO); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico dell'Italia Meridionale (GOIM); Istituto Oncologico Romagnolo (IOR); Gruppo Cooperativo Chirurgico Italiano (GOCCI); Gruppo Oncologico Nord Ovest (GONO); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC); Gruppo Cooperativo do Cancro Digestivo da Associação Portuguesa de Investigação Oncológica (GCCD, APIO); Grupo Español para el Tratamiento de los Tumores Digestivos (TTD); John Allen Bridgewater.

Eur J Cancer. 2017 Sep;82:16-24. doi: 10.1016/j.ejca.2017.04.025. Epub 2017 Jun 23.

PMID:
28651158
16.

Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study).

Garlan F, Laurent-Puig P, Sefrioui D, Siauve N, Didelot A, Sarafan-Vasseur N, Michel P, Perkins G, Mulot C, Blons H, Taieb J, Di Fiore F, Taly V, Zaanan A.

Clin Cancer Res. 2017 Sep 15;23(18):5416-5425. doi: 10.1158/1078-0432.CCR-16-3155. Epub 2017 Jun 2.

PMID:
28576867
17.

6-mercaptopurine promotes energetic failure in proliferating T cells.

Fernández-Ramos AA, Marchetti-Laurent C, Poindessous V, Antonio S, Laurent-Puig P, Bortoli S, Loriot MA, Pallet N.

Oncotarget. 2017 Jun 27;8(26):43048-43060. doi: 10.18632/oncotarget.17889.

18.

Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.

Garlan F, Blanchet B, Kramkimel N, Puszkiel A, Golmard JL, Noe G, Dupin N, Laurent-Puig P, Vidal M, Taly V, Thomas-Schoemann A.

Target Oncol. 2017 Jun;12(3):365-371. doi: 10.1007/s11523-017-0491-8.

PMID:
28527094
19.

Clinicopathologic Characteristics of Endometrial Cancer in Lynch Syndrome: A French Multicenter Study.

Rossi L, Le Frere-Belda MA, Laurent-Puig P, Buecher B, De Pauw A, Stoppa-Lyonnet D, Canlorbe G, Caron O, Borghese B, Colas C, Delhomelle H, Chabbert-Buffet N, Grandjouan S, Lecuru F, Bats AS.

Int J Gynecol Cancer. 2017 Jun;27(5):953-960. doi: 10.1097/IGC.0000000000000985.

PMID:
28525912
20.

Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy.

Roussel H, De Guillebon E, Biard L, Mandavit M, Gibault L, Fabre E, Antoine M, Hofman P, Beau-Faller M, Blons H, Danel C, Barthes FLP, Gey A, Granier C, Wislez M, Laurent-Puig P, Oudard S, Bruneval P, Badoual C, Cadranel J, Tartour E.

Oncoimmunology. 2017 Feb 21;6(4):e1286437. doi: 10.1080/2162402X.2017.1286437. eCollection 2017.

21.

3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer.

Lutz MP, Zalcberg JR, Ducreux M, Aust D, Bruno MJ, Büchler MW, Delpero JR, Gloor B, Glynne-Jones R, Hartwig W, Huguet F, Laurent-Puig P, Lordick F, Maisonneuve P, Mayerle J, Martignoni M, Neoptolemos J, Rhim AD, Schmied BM, Seufferlein T, Werner J, van Laethem JL, Otto F.

Eur J Cancer. 2017 Jul;79:41-49. doi: 10.1016/j.ejca.2017.03.022. Epub 2017 Apr 29.

22.

Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy.

Auclin E, Zaanan A, Vernerey D, Douard R, Gallois C, Laurent-Puig P, Bonnetain F, Taieb J.

Ann Oncol. 2017 May 1;28(5):958-968. doi: 10.1093/annonc/mdx030.

PMID:
28453690
23.

Erratum to: Partnering with patients in translational oncology research: ethical approach.

Mamzer MF, Duchange N, Darquy S, Marvanne P, Rambaud C, Marsico G, Cerisey C, Scotté F, Burgun A, Badoual C, Laurent-Puig P, Hervé C.

J Transl Med. 2017 Apr 23;15(1):80. doi: 10.1186/s12967-017-1181-0. No abstract available.

24.

Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities.

Pécuchet N, Vieira T, Rabbe N, Antoine M, Blons H, Cadranel J, Laurent-Puig P, Wislez M.

Ann Oncol. 2017 Jul 1;28(7):1597-1604. doi: 10.1093/annonc/mdx162.

PMID:
28419182
25.

Women Epidemiology Lung Cancer (WELCA) study: reproductive, hormonal, occupational risk factors and biobank.

Stücker I, Martin D, Neri M, Laurent-Puig P, Blons H, Antoine M, Guiochon-Mantel A, Brailly-Tabard S, Canonico M, Wislez M, Trédaniel J; WELCA study group.

BMC Public Health. 2017 Apr 17;17(1):324. doi: 10.1186/s12889-017-4191-1.

26.

Partnering with patients in translational oncology research: ethical approach.

Mamzer MF, Duchange N, Darquy S, Marvanne P, Rambaud C, Marsico G, Cerisey C, Scotté F, Burgun A, Badoual C, Laurent-Puig P, Hervé C.

J Transl Med. 2017 Apr 8;15(1):74. doi: 10.1186/s12967-017-1177-9. Erratum in: J Transl Med. 2017 Apr 23;15(1):80.

27.

Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.

Bradley CA, Salto-Tellez M, Laurent-Puig P, Bardelli A, Rolfo C, Tabernero J, Khawaja HA, Lawler M, Johnston PG, Van Schaeybroeck S; MErCuRIC consortium.

Nat Rev Clin Oncol. 2017 Sep;14(9):562-576. doi: 10.1038/nrclinonc.2017.40. Epub 2017 Apr 4. Review. Erratum in: Nat Rev Clin Oncol. 2018 Jan 23;:.

PMID:
28374784
28.

CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification.

Pilati C, Taieb J, Balogoun R, Marisa L, de Reyniès A, Laurent-Puig P.

Ann Oncol. 2017 May 1;28(5):1032-1035. doi: 10.1093/annonc/mdx066.

PMID:
28328000
29.

Molecular Tumor Boards: Ethical Issues in the New Era of Data Medicine.

Stoeklé HC, Mamzer-Bruneel MF, Frouart CH, Le Tourneau C, Laurent-Puig P, Vogt G, Hervé C.

Sci Eng Ethics. 2018 Feb;24(1):307-322. doi: 10.1007/s11948-017-9880-8. Epub 2017 Mar 9.

30.

Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas.

Pilati C, Shinde J, Alexandrov LB, Assié G, André T, Hélias-Rodzewicz Z, Ducoudray R, Le Corre D, Zucman-Rossi J, Emile JF, Bertherat J, Letouzé E, Laurent-Puig P.

J Pathol. 2017 May;242(1):10-15. doi: 10.1002/path.4880. Epub 2017 Mar 29.

PMID:
28127763
31.

Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.

Taieb J, Le Malicot K, Shi Q, Penault Lorca F, Bouché O, Tabernero J, Mini E, Goldberg RM, Folprecht G, Luc Van Laethem J, Sargent DJ, Alberts SR, Emile JF, Laurent Puig P, Sinicrope FA.

J Natl Cancer Inst. 2016 Dec 31;109(5). pii: djw272. doi: 10.1093/jnci/djw272. Print 2017 May.

PMID:
28040692
32.

Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.

Taieb J, Balogoun R, Le Malicot K, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Emile JF, Mulot C, Fratté S, Levaché CB, Saban-Roche L, Thaler J, Petersen LN, Bridgewater J, Perkins G, Lepage C, Van Cutsem E, Zaanan A, Laurent-Puig P; PETACC8 Investigators.

Ann Oncol. 2017 Apr 1;28(4):824-830. doi: 10.1093/annonc/mdw687.

PMID:
28031175
33.

Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.

Pécuchet N, Zonta E, Didelot A, Combe P, Thibault C, Gibault L, Lours C, Rozenholc Y, Taly V, Laurent-Puig P, Blons H, Fabre E.

PLoS Med. 2016 Dec 27;13(12):e1002199. doi: 10.1371/journal.pmed.1002199. eCollection 2016 Dec.

34.

Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker.

Pietrasz D, Pécuchet N, Garlan F, Didelot A, Dubreuil O, Doat S, Imbert-Bismut F, Karoui M, Vaillant JC, Taly V, Laurent-Puig P, Bachet JB.

Clin Cancer Res. 2017 Jan 1;23(1):116-123. doi: 10.1158/1078-0432.CCR-16-0806. Epub 2016 Dec 19.

35.

Erratum to: Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression.

Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautès-Fridman C, Fridman WH, de Reyniès A.

Genome Biol. 2016 Dec 1;17(1):249. No abstract available.

36.

Analysis of Base-Position Error Rate of Next-Generation Sequencing to Detect Tumor Mutations in Circulating DNA.

Pécuchet N, Rozenholc Y, Zonta E, Pietrasz D, Didelot A, Combe P, Gibault L, Bachet JB, Taly V, Fabre E, Blons H, Laurent-Puig P.

Clin Chem. 2016 Nov;62(11):1492-1503. Epub 2016 Sep 13.

37.

Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression.

Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautès-Fridman C, Fridman WH, de Reyniès A.

Genome Biol. 2016 Oct 20;17(1):218. Erratum in: Genome Biol. 2016 Dec 1;17 (1):249.

38.

BCL-2 system analysis identifies high-risk colorectal cancer patients.

Lindner AU, Salvucci M, Morgan C, Monsefi N, Resler AJ, Cremona M, Curry S, Toomey S, O'Byrne R, Bacon O, Stühler M, Flanagan L, Wilson R, Johnston PG, Salto-Tellez M, Camilleri-Broët S, McNamara DA, Kay EW, Hennessy BT, Laurent-Puig P, Van Schaeybroeck S, Prehn JHM.

Gut. 2017 Dec;66(12):2141-2148. doi: 10.1136/gutjnl-2016-312287. Epub 2016 Sep 23.

PMID:
27663504
39.

A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer.

Salvucci M, Würstle ML, Morgan C, Curry S, Cremona M, Lindner AU, Bacon O, Resler AJ, Murphy ÁC, O'Byrne R, Flanagan L, Dasgupta S, Rice N, Pilati C, Zink E, Schöller LM, Toomey S, Lawler M, Johnston PG, Wilson R, Camilleri-Broët S, Salto-Tellez M, McNamara DA, Kay EW, Laurent-Puig P, Van Schaeybroeck S, Hennessy BT, Longley DB, Rehm M, Prehn JH.

Clin Cancer Res. 2017 Mar 1;23(5):1200-1212. doi: 10.1158/1078-0432.CCR-16-1084. Epub 2016 Sep 20.

PMID:
27649552
40.

Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic Screening.

Damon C, Luck M, Toullec L, Etienne I, Buchler M, Hurault de Ligny B, Choukroun G, Thierry A, Vigneau C, Moulin B, Heng AE, Subra JF, Legendre C, Monnot A, Yartseva A, Bateson M, Laurent-Puig P, Anglicheau D, Beaune P, Loriot MA, Thervet E, Pallet N.

Am J Transplant. 2017 Apr;17(4):1008-1019. doi: 10.1111/ajt.14040. Epub 2016 Oct 7.

PMID:
27597269
41.

Integrating Heterogeneous Biomedical Data for Cancer Research: the CARPEM infrastructure.

Rance B, Canuel V, Countouris H, Laurent-Puig P, Burgun A.

Appl Clin Inform. 2016 May 4;7(2):260-74. doi: 10.4338/ACI-2015-09-RA-0125. eCollection 2016.

42.

Urinary Angiogenin Reflects the Magnitude of Kidney Injury at the Infrahistologic Level.

Tavernier Q, Mami I, Rabant M, Karras A, Laurent-Puig P, Chevet E, Thervet E, Anglicheau D, Pallet N.

J Am Soc Nephrol. 2017 Feb;28(2):678-690. doi: 10.1681/ASN.2016020218. Epub 2016 Jul 19.

43.

Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations.

Zonta E, Garlan F, Pécuchet N, Perez-Toralla K, Caen O, Milbury C, Didelot A, Fabre E, Blons H, Laurent-Puig P, Taly V.

PLoS One. 2016 Jul 14;11(7):e0159094. doi: 10.1371/journal.pone.0159094. eCollection 2016.

44.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D.

Ann Oncol. 2016 Aug;27(8):1386-422. doi: 10.1093/annonc/mdw235. Epub 2016 Jul 5.

PMID:
27380959
45.

Intratumoral Immune Cell Densities Are Associated with Lung Adenocarcinoma Gene Alterations.

Mansuet-Lupo A, Alifano M, Pécuchet N, Biton J, Becht E, Goc J, Germain C, Ouakrim H, Régnard JF, Cremer I, Laurent-Puig P, Dieu-Nosjean MC, Blons H, Damotte D.

Am J Respir Crit Care Med. 2016 Dec 1;194(11):1403-1412.

PMID:
27299180
46.

Women at a Disadvantage in Fluorouracil Treatment-Reply.

Boige V, Vincent M, Laurent-Puig P.

JAMA Oncol. 2016 Jun 1;2(6):830-1. doi: 10.1001/jamaoncol.2016.1089. No abstract available.

PMID:
27281626
47.

A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker.

Garrigou S, Perkins G, Garlan F, Normand C, Didelot A, Le Corre D, Peyvandi S, Mulot C, Niarra R, Aucouturier P, Chatellier G, Nizard P, Perez-Toralla K, Zonta E, Charpy C, Pujals A, Barau C, Bouché O, Emile JF, Pezet D, Bibeau F, Hutchison JB, Link DR, Zaanan A, Laurent-Puig P, Sobhani I, Taly V.

Clin Chem. 2016 Aug;62(8):1129-39. doi: 10.1373/clinchem.2015.253609. Epub 2016 Jun 1.

48.

Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy.

Becht E, de Reyniès A, Giraldo NA, Pilati C, Buttard B, Lacroix L, Selves J, Sautès-Fridman C, Laurent-Puig P, Fridman WH.

Clin Cancer Res. 2016 Aug 15;22(16):4057-66. doi: 10.1158/1078-0432.CCR-15-2879. Epub 2016 Mar 18.

49.

Fine-mapping of two differentiated thyroid carcinoma susceptibility loci at 9q22.33 and 14q13.3 detects novel candidate functional SNPs in Europeans from metropolitan France and Melanesians from New Caledonia.

Tcheandjieu C, Lesueur F, Sanchez M, Baron-Dubourdieu D, Guizard AV, Mulot C, Laurent-Puig P, Schvartz C, Truong T, Guenel P.

Int J Cancer. 2016 Aug 1;139(3):617-27. doi: 10.1002/ijc.30088. Epub 2016 Mar 30.

50.

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.

Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M, Fredriksen T, Sasso M, Bilocq AM, Kirilovsky A, Obenauf AC, Hamieh M, Berger A, Bruneval P, Tuech JJ, Sabourin JC, Le Pessot F, Mauillon J, Rafii A, Laurent-Puig P, Speicher MR, Trajanoski Z, Michel P, Sesboüe R, Frebourg T, Pagès F, Valge-Archer V, Latouche JB, Galon J.

Immunity. 2016 Mar 15;44(3):698-711. doi: 10.1016/j.immuni.2016.02.025.

Supplemental Content

Loading ...
Support Center